O
OrbiMed Portfolio holdings
AUM
$5.4B
Turnover
40.13%
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
-4.57%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$9.89B
AUM Growth
-$808M
(-7.6%)
Cap. Flow
+$275M
Cap. Flow
% of AUM
2.78%
Top 10 Holdings %
Top 10 Hldgs %
30.49%
Holding
183
New
24
Increased
25
Reduced
25
Closed
24
Avg Time Held Equity + Options
1.7
years
Top 10 Avg Time Held Equity + Options
0.5
years
Top 20 Avg Time Held Equity + Options
1.6
years
Avg Time Held Equity only
1.7
years
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
1.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P Biotech ETF
XBI
|
+$123M |
| 2 |
Neuropace
NPCE
|
+$93.1M |
| 3 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$77.8M |
| 4 |
Janux Therapeutics
JANX
|
+$77.2M |
| 5 |
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$74.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Haemonetics
HAE
|
+$94.6M |
| 2 |
AbCellera Biologics
ABCL
|
+$54.5M |
| 3 |
Adverum Biotechnologies
ADVM
|
+$54.2M |
| 4 |
Molina Healthcare
MOH
|
+$38M |
| 5 |
PAND
Pandion Therapeutics Inc. Common Stock
PAND
|
+$31.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.72% |
| 2 | Miscellaneous | 4.15% |
| 3 | Technology | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
DELISTED
Inozyme Pharma
INZY
| $3.22M | 0.03% |
+188,704
| New | +$3.28M |
2021 Q2
0 quarters
|
|
152
InflaRx
IFRX
$218M
| $3.16M | 0.03% |
1,064,118
| – | – |
2020 Q1
5 quarters
|
|
153
DELISTED
Kezar Life Sciences
KZR
| $3.03M | 0.03% |
+55,719
| New | +$3.16M |
2021 Q2
0 quarters
|
|
154
CALL
DELISTED
CureVac
CVAC
| $2.2M | 0.02% |
+30,000
| New | +$3M |
2021 Q2
0 quarters
|
|
155
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $1.03M | 0.01% |
113,500
-186,500
| -62% | -$1.86M |
2021 Q1
1 quarter
|
|
156
CALL
DELISTED
WM TECHNOLOGY INC WTS
MAPSW
| $954K | 0.01% |
+150,200
| New | +$931K |
2021 Q2
0 quarters
|
|
157
Purple Biotech
PPBT
$2M
| $86K | ﹤0.01% |
89
-68
| -43% | -$62.5K |
2020 Q1
5 quarters
|
|
|
158
DELISTED
Adverum Biotechnologies
ADVM
| – | – |
-550,114
| Closed | -$54.2M | – |
|
159
Alignment Healthcare
ALHC
$1.71B
| – | – |
-800,000
| Closed | -$17.5M | – |
|
160
PUT
Axsome Therapeutics
AXSM
$8.5B
| – | – |
-50,000
| Closed | -$2.83M | – |
|
161
Compass Pathways
CMPS
$1.56B
| – | – |
-127,816
| Closed | -$4.71M | – |
|
162
PUT
CEL-SCI Corp
CVM
$30.1M
| – | – |
-3,333
| Closed | -$1.52M | – |
|
163
DELISTED
Forte Biosciences
FBRX
| – | – |
-6,387
| Closed | -$5.47M | – |
|
|
164
Haemonetics
HAE
$5.51B
| – | – |
-852,000
| Closed | -$94.6M | – |
|
165
Health Catalyst
HCAT
$131M
| – | – |
-179,598
| Closed | -$8.4M | – |
|
166
InnovAge Holding
INNV
$1.24B
| – | – |
-200,000
| Closed | -$5.16M | – |
|
167
CALL
Standard BioTools
LAB
$248M
| – | – |
-500,000
| Closed | -$2.26M | – |
|
168
Larimar Therapeutics
LRMR
$217M
| – | – |
-617,245
| Closed | -$9.02M | – |
|
|
169
DELISTED
WM TECHNOLOGY INC WTS
MAPSW
| – | – |
-150,200
| Closed | -$931K | – |
|
|
170
Molina Healthcare
MOH
$10.9B
| – | – |
-162,400
| Closed | -$38M | – |
|
171
Intellia Therapeutics
NTLA
$1.6B
| – | – |
-72,500
| Closed | -$5.82M | – |
|
172
Nuvation Bio
NUVB
$1.64B
| – | – |
-800,000
| Closed | -$8.36M | – |
|
173
Cartesian Therapeutics
RNAC
$192M
| – | – |
-11,306
| Closed | -$1.53M | – |
|
174
Sana Biotechnology
SANA
$698M
| – | – |
-60,000
| Closed | -$2.01M | – |
|
175
Travere Therapeutics
TVTX
$5.02B
| – | – |
-528,100
| Closed | -$13.2M | – |
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q2 2021 Portfolio in Review
As of Q2 2021, OrbiMed held 183 positions worth $9.89B, down 7.6% from $10.7B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
OrbiMed's Q2 2021 filing shows 24 new, 25 increased, 25 reduced and 24 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M. The largest sale was Haemonetics, an estimated $94.6M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Technology.
- OrbiMed's largest Q2 2021 buy was State Street SPDR S&P Biotech ETF: 935,700 shares worth $127M.
- OrbiMed added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2021, an estimated $74.2M increase.
- OrbiMed's biggest Q2 2021 reduction was AbCellera Biologics, cutting an estimated $54.5M.
- OrbiMed fully exited Haemonetics in Q2 2021, selling an estimated $94.6M.
- OrbiMed's ten largest holdings make up 30% of its $9.89B portfolio in Q2 2021.
- OrbiMed opened 24 new positions and closed 24 in Q2 2021.
- OrbiMed's portfolio value fell 7.6% quarter-over-quarter to $9.89B.
Based on OrbiMed's 13F filing for Q2 2021, filed 16 Aug 2021.